2022 Fiscal Year Final Research Report
Development of a therapeutic vaccine for dyslipidemia
Project/Area Number |
21K20935
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Multi-year Fund |
Review Section |
0904:Internal medicine of the bio-information integration and related fields
|
Research Institution | Kumamoto University |
Principal Investigator |
|
Project Period (FY) |
2021-08-30 – 2023-03-31
|
Keywords | ANGPTL3 / 脂質異常症 / ペプチドワクチン / 家族性高コレステロール血症 |
Outline of Final Research Achievements |
We have initiated the development of a peptide vaccine targeting Angiopoietin-like protein 3 (ANGPTL3) and have identified a peptide sequence (E3) that demonstrates an ameliorating effect on dyslipidemia (Fukami and Morinaga et al., Cell Reports Medicine, 2021; Patent application: JP 2021-84971; PCT/JP2022/20850). In an assessment of the vaccine's durability in wild-type mice, the antibody titer and the suppression of circulating triglyceride levels were maintained for 60 weeks after the first administration. Furthermore, booster vaccinations sustained the antibody titer until 113 weeks of age, and no apparent adverse reactions were observed during this period.
|
Free Research Field |
腎臓内科学、内分泌代謝学
|
Academic Significance and Societal Importance of the Research Achievements |
本研究ワクチンは、ANGPTL3を標的とした既存のバイオ医薬品に比し安価な新規薬剤となり、発展途上国等での普及も期待される。また、半年から年に1回投与で効果が期待できることから、 経済的な負担軽減に加え、接種による疼痛の頻度を減らすことで患者のアドヒアランス向上に寄与できる。本研究は多くの治療抵抗性脂質異常症に対する効果的かつ安価な薬剤提供を実現するためのスタートアップと位置付けられる重要な研究基盤となる。
|